Jacksonville, FL - Data from a pharmacodynamic study suggests that acute coronary syndrome (ACS) patients can be safely switched from maintenance clopidogrel (Plavix, Bristol-Myers ...

When choosing between potent P2Y12 inhibitors in ACS patients managed with an invasive strategy, renal function should not be a deciding factor, a prespecified analysis of the ISAR-REACT 5 trial ...

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors-ticagrelor or prasugrel-in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the ...

Among patients with ACS who undergo PCI, a prasugrel-based strategy is superior to one using ticagrelor in terms of all-cause death, MI, and stroke at 12 months, according to a prespecified ...

Hazard ratio of the primary outcome was 24% higher in individuals treated with ticagrelor. Risks were also significantly higher for MI and stroke among people treated with ticagrelor. Risks for the ...

One year of treatment with either of two strong blood-thinning medications - ticagrelor and prasugrel - by people with type 1 or type 2 diabetes who had a drug-eluting stent placed in their heart to ...

MUNICH, Aug 31 (Reuters) - Eli Lilly and Daiichi Sankyo's <4568.T> new blood-thinning drug prasugrel appears better for diabetes patients than Plavix, researchers said on Sunday. Prasugrel -- a rival ...

SAN DIEGO, CA — In a small Phase 2 study presented at the 53 rd American Society of Hematology’s Annual Meeting and Exposition, once-daily prasugrel 5mg for 30 days showed some promise of decreasing ...

NEW ORLEANS, Nov 10 (Reuters) - Researchers have overestimated the ability to administer Eli Lilly and Co's experimental prasugrel blood thinner without causing dangerous bleeding, a prominent ...

Based in the Philadelphia area, Charles V. Pollack, MD, has more than 35 years of experience as a researcher, clinical ...